

DIAGNOSTIC NOTE TEMPLATE

SOAP NOTE TEMPLATE WHEN CONSIDERING A DIAGNOSIS OF IDIOPATHIC PULMONARY FIBROSIS (IPF)

| | | | | |
|------------------------|------------------------------------|--|--|--|
| SUBJECTIVE | CHIEF COMPLAINT: | <hr/> <hr/> <hr/> <hr/> | | |
| | HISTORY OF PRESENT ILLNESS: | <p>Consider IPF as possible diagnosis if any of the following applies¹:</p> <ul style="list-style-type: none"> - >50 years of age with any of the following: - Chronic cough - Dyspnea upon exertion - History of smoking | | |
| | MEDICAL HISTORY: | Medical Conditions | Medications | |
| | | <p>It is important to rule out other causes of ILD such as: connective tissue disease-related interstitial lung disease, chronic hypersensitivity pneumonitis, sarcoidosis, and radiation- and drug-induced lung disease¹</p> | <p>Inquire specifically about pneumotoxic drugs³</p> <hr/> <hr/> <hr/> <hr/> | |
| | SMOKING HISTORY: | <p>The following comorbidities are common in patients with IPF²:</p> <ul style="list-style-type: none"> - Cardiovascular disease - Chronic obstructive pulmonary disease - Gastroesophageal reflux disease - Lung cancer - Metabolic disorders - Obstructive sleep apnea - Pulmonary arterial hypertension - Pulmonary embolism <p><small>*Listed in alphabetical order</small></p> | | <hr/> <hr/> <hr/> <hr/> <hr/> <hr/> <hr/> <hr/> |
| | | <hr/> <hr/> <hr/> <hr/> | | <p>Consider IPF as a possible diagnosis if patient presents with a smoking history⁴</p> |
| FAMILY HISTORY: | <hr/> <hr/> <hr/> <hr/> | | <p>Consider IPF as a possible diagnosis if patient presents with a family history of IPF¹</p> | |
| SOCIAL HISTORY: | <hr/> <hr/> <hr/> <hr/> | | <p>Ensure work history and environmental exposures are discussed to rule out other causes of ILD¹</p> | |

VITAL SIGNS:

SEROLOGICAL TESTING:

Consider IPF as a possible diagnosis if autoimmune workup is negative and other features consistent with IPF are positive¹

LUNG AUSCULTATION:

Consider IPF as a possible diagnosis if patient demonstrates inspiratory, bibasilar "Velcro®-like" crackles¹

LUNG FUNCTION:

| Lung Volume | Flow | Gas Exchange |
|-------------|------------------------------|--------------------------|
| TLC: _____ | FEV ₁ : _____ | DL _{co} : _____ |
| _____ | FVC: _____ | _____ |
| _____ | FEV ₁ /FVC: _____ | _____ |
| _____ | _____ | _____ |

Consider IPF as a possible diagnosis if patient demonstrates the following lung function results:

- Reduced TLC and/or FVC¹
- FEV₁/FVC consistent with restrictive pattern

NOTE: In certain situations, IPF patients may exhibit normal or obstructive patterns if concomitant obstructive disease exists. Therefore, while a restrictive pattern is indicative of IPF, lacking a restrictive pattern does not preclude an IPF diagnosis.

- Reduced DL_{co}¹

TLC = total lung capacity; FEV = forced expiratory volume in 1 second; FVC = forced vital capacity; DL_{co} = diffusing capacity of lung for carbon monoxide

EXERCISE CAPACITY:

| Oxygen Saturation with Exertion (6-MWT) | Oxygen Saturation at Rest |
|---|---------------------------|
| _____ | _____ |
| _____ | _____ |

Consider IPF as a possible diagnosis if patient demonstrates the following exercise testing results:

- Low oxygenation

6-MWT = 6-minute walk test

RADIOGRAPHIC ASSESSMENT:

Order chest HRCT when considering IPF

For quality imaging, ensure HRCT is conducted using proper technique⁴:

- Slice thickness ≤2 mm
- Noncontrast conditions
- Full inspiration without respiratory motion
- Field of view to include lungs only
 - High-resolution reconstruction algorithm

List not exhaustive. Please see reference 4.

Consider IPF if HRCT shows a pattern of usual interstitial pneumonia (UIP)¹:

- Predominant subpleural distribution
- Reticular abnormalities
- Honeycombing
- Absence of features inconsistent with UIP

In cases of possible UIP*, consider pathological assessment

*The ATS diagnostic guidelines are based on categorization of HRCT patterns such as UIP, possible UIP, and inconsistent with UIP. The Fleischner Society has since released a white paper with revised categories: typical UIP, probable UIP, and indeterminate for UIP. The white paper states that a confident diagnosis of IPF can be made in the correct clinical context with a radiographic pattern of typical or probable UIP. The ATS guidelines may be updated to reflect the revised categories.⁵

DIAGNOSIS:

Include IPF in your differential diagnosis if other known causes have been excluded and a UIP pattern is present on HRCT¹

MANAGEMENT PLAN:

Initiate a comprehensive management plan and consider the following:

- Pharmacologic treatment and nonpharmacologic treatments are important to comprehensive patient management⁶
 - FDA-approved, IPF-specific therapy; management of comorbidities; symptom management; clinical trials enrollment⁶⁻⁸
 - Supplemental oxygen, pulmonary rehabilitation, disease education, psychosocial support, evaluation for lung transplant, and palliative care¹
- Consider comorbidities and concomitant medications when selecting the most appropriate management plan⁷
- Manage comorbidities as medically appropriate⁷
- Monitor disease progression at least every 6 months or as medically appropriate¹
- A collaborative conversation with your patients can encourage them to follow their management plan⁹
 - Important information to communicate when discussing IPF with your patients includes:
 - The patient's lung function will deteriorate at any time, so intervening upon diagnosis is crucial^{10,11}
 - Educate patients on management options for IPF⁶
 - Adhering to a management plan is important to managing IPF and associated comorbidities⁷
- Provide support for caregivers⁷
- Schedule next follow-up

References:

1. Raghu, et al. *Am J Respir Crit Care Med*. 2011;183:788-824.
2. Raghu, et al. *Eur Respir J*. 2015;46:1113-1130.
3. Mayo Clinic website. <http://www.mayoclinic.org/diseases-conditions/interstitial-lung-disease/basics/causes/con-20024481>. Accessed December 4, 2017.
4. Raghu, et al. *Am J Respir Crit Care Med*. 2011;183:788-824 (online supplement).
5. Lynch, et al. Published online ahead of print November 15, 2017. *Lancet Respir Med*. doi: 10.1016/S2213-2600(17)30433-2. Accessed December 4, 2017.
6. Raghu, et al. *Am J Respir Crit Care Med*. 2015;192:e3-e19.
7. Lee, et al. *Curr Opin Pulm Med*. 2011;17:348-354.
8. Padilla. *Am J Manag Care*. 2015;21(suppl 14):s276-s283.
9. Pulmonary Fibrosis Foundation. *Pulmonary Fibrosis Patient Information Guide*. Chicago, IL: Pulmonary Fibrosis Foundation; 2015.
10. Cottin and Richeldi. *Eur Respir Rev*. 2014;23:106-110.
11. Ley, et al. *Am J Respir Crit Care Med*. 2011;183:431-440.

FOLLOW-UP NOTE TEMPLATE

SOAP NOTE TEMPLATE WHEN MANAGING A PATIENT WITH IPF

SUBJECTIVE

CHIEF COMPLAINT:

HISTORY OF PRESENT ILLNESS:

Evaluate for change in symptoms and oxygen requirement, and determine whether these are due to IPF- or non-IPF-related causes¹

MEDICAL HISTORY:

Medical Conditions

Medications

Any updates since last visit?

SMOKING HISTORY:

If patient is a current smoker, stress the benefits of quitting²

FAMILY HISTORY:

Any updates since last visit?

SOCIAL HISTORY:

VITAL SIGNS:

LUNG AUSCULTATION:

Any change since last visit? Presence of inspiratory, bibasilar "Velcro®-like" crackles?

LUNG FUNCTION:

| Lung Volume | Flow | Gas Exchange |
|-------------|------------------------------|--------------------------|
| TLC: _____ | FEV ₁ : _____ | DL _{CO} : _____ |
| _____ | FVC: _____ | _____ |
| _____ | FEV ₁ /FVC: _____ | _____ |
| _____ | _____ | _____ |
| _____ | _____ | _____ |

Monitor every 3-6 months or as medically appropriate¹

TLC = total lung capacity; FEV₁ = forced expiratory volume in 1 second; FVC = forced vital capacity; DL_{CO} = diffusing capacity of lung for carbon monoxide

EXERCISE CAPACITY:

| Oxygen Saturation with Exertion (6-MWT) | Oxygen Saturation at Rest |
|---|---------------------------|
| _____ | _____ |
| _____ | _____ |
| _____ | _____ |

Monitor every 3-6 months or as medically appropriate¹

DIAGNOSIS:

Any change in disease status or new diagnoses since last visit?

MANAGEMENT PLAN:

- Continue to implement a comprehensive management plan and consider the following:
- Pharmacologic treatment and nonpharmacologic treatments are important to comprehensive patient management³
 - FDA-approved, IPF-specific therapy; management of comorbidities; symptom management; clinical trials enrollment²⁻⁴
 - Supplemental oxygen, pulmonary rehabilitation, disease education, psychosocial support, evaluation for lung transplant, and palliative care¹
 - Consider comorbidities and concomitant medications when selecting the most appropriate management plan²
 - Manage comorbidities as medically appropriate²
 - Monitor disease progression at least every 6 months or as medically appropriate¹
 - A collaborative conversation with your patients can encourage them to follow their management plan⁵
 - Important information to communicate when discussing IPF with your patients includes:
 - The patient's lung function will deteriorate at any time, so intervening upon diagnosis is crucial^{6,7}
 - Educate patients on management options for IPF³
 - Adhering to a management plan is important to managing IPF and associated comorbidities²
 - Provide support for caregivers²
 - Schedule next follow-up

References:

1. Raghu, et al. *Am J Respir Crit Care Med*. 2011;183:788-824.
2. Lee, et al. *Curr Opin Pulm Med*. 2011;17:348-354.
3. Raghu, et al. *Am J Respir Crit Care Med*. 2015;192:e3-e19.
4. Padilla. *Am J Manag Care*. 2015;21(suppl 14):s276-s283.
5. Pulmonary Fibrosis Foundation. *Pulmonary Fibrosis Patient Information Guide*. Chicago, IL: Pulmonary Fibrosis Foundation; 2015.
6. Cottin and Richeldi. *Eur Respir Rev*. 2014;23:106-110.
7. Ley, et al. *Am J Respir Crit Care Med*. 2011;183:431-440.